Patients may experience blurred vision or headache, fever and leukocytosis ... inflammation is lymphocytic pituitary inflammation, which is most frequent in pregnant or postpartum women. In turn, ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) patients with a new all-tablet treatment showing impressive results.

Research suggests that people with CLL may be more likely to develop COVID-19 due to advanced age, disease-related immunosuppression, and treatment-related immunosuppression. Taking precautions ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...